Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
976.8 DKK | -10.39% | -2.81% | -26.56% |
03-27 | Orphazyme A/S Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
03-04 | FDA Extends Review of Zevra's Arimoclomol by Three Months | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration1st Jan change | Capi. | |
---|---|---|
-26.56% | 5.51M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+0.47% | 22.15B | |
-17.37% | 21.02B | |
-8.31% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- ORPHA Stock
- News Orphazyme A/S
- Orphazyme A/S : Says European Review of Arimoclomol Underway; Raises 2021 Cash Position Outlook